News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Evolva (EVE.SW) Awarded Contract By U.S. Government To Advance Novel Pest Control Product



9/11/2017 7:34:13 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

REINACH, Switzerland--(BUSINESS WIRE)--Evolva announced today that it has finalized negotiations for a contract with the US government. The key objective of this contract is to advance the development of safe, effective, and sustainably sourced next-generation products that can provide a new form of protection against select mosquito-borne diseases like Zika.

Nootkatone can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (also known as the Nootka cypress), or produced in a sustainable, industrial scale process via yeast fermentation that provides a reliable, safe supply.

This CDC-funded contract is worth $8.35 million to Evolva, will run for 18 months, and will begin immediately.

Evolva has been working in close collaboration with the CDC on the use of nootkatone against a wide variety of biting pests, such as mosquitoes and ticks that can cause disease. The goal is that nootkatone can one day be used not just against the Aedes aegypti mosquito that transmits Zika virus, but also for the benefit of global public health against other important biting pests, such as Ixodes tick vectors of Lyme disease and the mosquitoes that spread West Nile and other viruses.

This contract supports Evolva’s strategy to advance to the market safe, effective, sustainably produced, next-generation products that offer the potential for meaningful new protection from biting pests.

About Evolva

Evolva solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolva.com. Questions about our approach? Have a look at our video.

About nootkatone

Nootkatone is a citrus ingredient that is characteristically associated with grapefruit. It can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (also known as the Nootka cypress), or produced on an industrial scale from brewing via yeast fermentation. Nootkatone is being tested against a variety of biting and nuisance pests, including the ticks that are responsible for spreading Lyme disease and the mosquitoes contributing to the spread of diseases such as Zika, chikungunya, dengue and West Nile viruses.

About Evolva’s collaboration with CDC and BARDA

This project has been funded in whole with Federal funds from the Centers for Disease Control and Prevention (CDC), and managed by the Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), under Contract No. HHSO100201700015C.

About Lyme disease and Zika virus

Lyme disease is caused by the bacterium Borrelia burgdorferi and is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans. If left untreated, infection can spread to joints, the heart, and the nervous system. Zika virus disease (Zika) is a disease caused by Zika virus that is spread to people primarily through the bite of an infected Aedes aegypti or Ae. albopictus species mosquito. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). Because the symptoms of Zika are similar to those of many other diseases, many cases may not have been recognised.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Evolva
Media
Stephan Herrera, + 1 415-794-4005
stephanh@evolva.com
or
IR
Paul Verbraeken, + 41 61 485 20 35
paulv@evolva.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES